44 research outputs found
Infective and nonbacterial thrombotic endocarditis in patients with post-COVID-19 viral-immune myocarditis
The possibility of heart inflammation (both myocardial and endocardial) months after a coronavirus disease 2019 (COVID-19) has not been practically studied, especially since approaches to the treatment of myocarditis in combination with various endocarditis forms have not been developed.Aim. To study the prevalence and mechanisms of SARS-CoV-2-associated endocardial injury in patients with morphologically verified post-COVID-19 myocarditis, as well as to develop approaches to comprehensive therapy.Material and methods. The study included 18 patients with severe morphologically verified post-COVID-19 myocarditis (men, 9; 51,1±9,4 years; 35 to 66 years). Patients with prior verified myocarditis/myocardial infarction, rheumatic heart disease, and systemic immune diseases were excluded. The average time after COVID-19 was 6,5 [3.5; 10] months The diagnosis of myocarditis was confirmed by endomyocardial biopsy (including immunohistochemical examination with antibodies to CD3, CD20, CD45, CD68, and to SARS-CoV-2 antigens; polymerase chain reaction for SARS-CoV-2 RNA, DNA of cardiotropic viruses). The blood level of anticardiac antibodies was determined by indirect immunofluorescence. In addition, echocardiography, magnetic resonance imaging (n=8), cardiac multislice tomography (n=1), and coronary angiography (n=14) were performed.Results. Biopsy revealed active (n=12) and borderline (n=3) lymphocytic myocarditis, eosinophilic (n=2) and giant cell (n=1) myocarditis. In 4 patients, nonbacterial thrombotic endocarditis (NBTE) with parietal and intravascular thrombosis was diagnosed, and in one patient â infective endocarditis (IE) of the bicuspid aortic valve. Myocardial persistence of SARS-CoV-2 was detected in 72% of cases (in 3 patients â with NBTE; in 1 â with IE; in 9 â without endocarditis). Titers of anticardiac antibodies increased by 3-4 times in 94% of patients. Patients with endocarditis were characterized by larger heart chambers, lower ejection fraction (27,5±6,6 vs 36,0±13,4%), more severe pulmonary hypertension, and valvular regurgitation. Intraventricular thrombosis according to echocardiography/magnetic resonance imaging and cardiac embolism was not observed. Treatment in all patients included methylprednisolone at an average dose of 24 mg a day. In 10 patients, the result was monitored for at least 3 months as follows: the ejection fraction was 46,0±12,7% and 44,3±7,3% in patients with and without endocarditis, respectively.Conclusion. Endocarditis in patients with post-COVID-19 myocarditis was detected in 28% (1 patient â IE; 4 â NBTE). The key mechanisms of post-COVID-19 myocarditis and NBTE are long-term (up to 18 months) myocardial persistence of SARS-Cov-2 and the development of an autoimmune reaction. Endocarditis was diagnosed in more severe patients, including those with giant cell and eosinophilic myocarditis. The effectiveness of steroid therapy in combination with anticoagulants in patients with NBTE requires further study. In case of IE, steroids can also be used in the treatment of myocarditis (in combination with antibiotics and immunoglobulin)
Multiparametric determination of genes and their point mutations for identification of beta-lactamases
ĐĐĄĐĄĐĐŠĐĐĐŠĐĐ ĐĐĐĐĐĐРЀĐĐĐĐ ĐĐĐĐ ADRA2B ĐĄ Đ€ĐĐĐąĐĐ ĐĐĐ Đ ĐĐĄĐĐ ĐĄĐĐ ĐĐЧĐĐ-ĐĄĐĐĄĐŁĐĐХйЫЄ ĐĐĐĐĐĐĐĐĐĐĐ Đ ĐĐĐĐŁĐĐŻĐŠĐĐ ĐĐĐ ĐĐĐĐ«Đ„ ĐĐĐąĐĐĐĐ ĐĐĐ ĐĐĐ ĐšĐĐ ĐĐ
Study objectives: examine the frequency of genotypes and alleles of I/D polymorphism of gene ADRA2B of native people living in Mountain Shoria (the Shors), as well as their association with risk factors for cardiovascular diseases.Material and methods. Overall 221 native people of Shoria were examined. The average age is51.07 ± 1.46 among males, 52.93 ± 0.96 among females (p = 0.286). Anthropometric characteristics, lipid levels of blood and I/D polymorphism of ADRA2B were studied.Results. DD genotype of the gene ADRA2B in the native population of the Shor people is associated with adiposis and high index of "waist/hip", hypertriglyceridemia. The average values of Quetelet index is higher in carriers of this genotype compared with carriers of genotype ID. Average waist indications in homozygous insertions were lower than those in homozygous deletions and heterozygotes. Patients with genotype DD have higher average levels of triglycerides, atherogenic index, cholesterol, very low density lipoproteins.Conclusion. DD allele ADRA2B genotype is responsible for adiposis and high levels of TG among native population of Shoria.ĐĐ°ŃŃĐœĐŸ-ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ŃДлŃŃĐșĐžĐč ĐžĐœŃŃĐžŃŃŃ ĐșĐŸĐŒĐżĐ»Đ”ĐșŃĐœŃŃ
ĐżŃĐŸĐ±Đ»Đ”ĐŒ ŃĐ”ŃĐŽĐ”ŃĐœĐŸ-ŃĐŸŃŃĐŽĐžŃŃŃŃ
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč ХОбОŃŃĐșĐŸĐłĐŸ ĐŸŃĐŽĐ”Đ»Đ”ĐœĐžŃ Đ ĐĐ, ĐĐ”ĐŒĐ”ŃĐŸĐČĐŸ; ĐĐŸĐČĐŸĐșŃĐ·ĐœĐ”ŃĐșĐžĐč ĐłĐŸŃŃĐŽĐ°ŃŃŃĐČĐ”ĐœĐœŃĐč ĐžĐœŃŃĐžŃŃŃ ŃŃĐŸĐČĐ”ŃŃĐ”ĐœŃŃĐČĐŸĐČĐ°ĐœĐžŃ ĐČŃĐ°ŃĐ”Đč, ĐĐŸĐČĐŸĐșŃĐ·ĐœĐ”ŃĐșĐŠĐ”Đ»Ń ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ â ОзŃŃĐžŃŃ ŃĐ°ŃŃĐŸŃŃ ĐłĐ”ĐœĐŸŃĐžĐżĐŸĐČ Đž аллДлДĐč I/D ĐżĐŸĐ»ĐžĐŒĐŸŃŃĐžĐ·ĐŒĐ° ĐłĐ”ĐœĐ° ADRA2B ĐČ ĐżĐŸĐżŃĐ»ŃŃОО ĐșĐŸŃĐ”ĐœĐœŃŃ
жОŃДлДĐč ĐĐŸŃĐœĐŸĐč ĐšĐŸŃОО (ŃĐŸŃŃĐ”ĐČ), Đ° ŃĐ°ĐșжД ĐžŃ
Đ°ŃŃĐŸŃОаŃĐžŃ Ń ŃĐ°ĐșŃĐŸŃĐ°ĐŒĐž ŃĐžŃĐșĐ° ŃĐ”ŃĐŽĐ”ŃĐœĐŸ-ŃĐŸŃŃĐŽĐžŃŃŃŃ
Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč.ĐĐ°ŃĐ”ŃОал Đž ĐŒĐ”ŃĐŸĐŽŃ. ĐŃĐŸĐČĐ”ĐŽĐ”ĐœĐŸ ĐșĐ»ĐžĐœĐžĐșĐŸ-ŃĐżĐžĐŽĐ”ĐŒĐžĐŸĐ»ĐŸĐłĐžŃĐ”ŃĐșĐŸĐ” ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐ” ĐșĐŸŃĐ”ĐœĐœĐŸĐłĐŸ ĐœĐ°ŃĐ”Đ»Đ”ĐœĐžŃ ŃŃŃĐŽĐœĐŸĐŽĐŸŃŃŃĐżĐœŃŃ
ŃĐ°ĐčĐŸĐœĐŸĐČ ĐĐŸŃĐœĐŸĐč ĐšĐŸŃОО. ĐĄĐżĐ»ĐŸŃĐœŃĐŒ ĐŒĐ”ŃĐŸĐŽĐŸĐŒ ĐŸĐ±ŃĐ»Đ”ĐŽĐŸĐČĐ°Đœ 221 ŃĐ”Đ»ĐŸĐČĐ”Đș, ĐČŃĐ±ĐŸŃĐșĐ° ŃĐŸŃŃĐŸŃла Оз ĐČĐ·ŃĐŸŃĐ»ĐŸĐłĐŸ ĐœĐ°ŃĐ”Đ»Đ”ĐœĐžŃ (лОŃĐ° ĐČ ĐČĐŸĐ·ŃĐ°ŃŃĐ” 18 Đ»Đ”Ń Đž ŃŃĐ°ŃŃĐ”). ĐĄŃĐ”ĐŽĐœĐžĐč ĐČĐŸĐ·ŃĐ°ŃŃ ĐŸĐ±ŃлДЎŃĐ”ĐŒŃŃ
ŃĐŸŃŃĐ°ĐČОл (51,07 ± 1,46) Đ»Đ”Ń Ń ĐŒŃжŃĐžĐœ, (52,93 ± 0,96) Đ»Đ”Ń Ń Đ¶Đ”ĐœŃĐžĐœ (p = 0,286). ĐĐ·ŃŃĐ”ĐœŃ Đ°ĐœŃŃĐŸĐżĐŸĐŒĐ”ŃŃĐžŃĐ”ŃĐșОД ĐŽĐ°ĐœĐœŃĐ”, ĐżĐŸĐșĐ°Đ·Đ°ŃДлО Đ»ĐžĐżĐžĐŽĐœĐŸĐłĐŸ ŃпДĐșŃŃĐ° ĐșŃĐŸĐČĐž, I/D ĐżĐŸĐ»ĐžĐŒĐŸŃŃĐžĐ·ĐŒ ĐłĐ”ĐœĐ° ADRA2B.РДзŃĐ»ŃŃĐ°ŃŃ. ĐĐ”ĐœĐŸŃОп DD ĐłĐ”ĐœĐ° ADRA2B ĐČ ĐżĐŸĐżŃĐ»ŃŃОО ŃĐŸŃŃĐ”ĐČ Đ°ŃŃĐŸŃООŃŃĐ”ŃŃŃ Ń ĐŸĐ¶ĐžŃĐ”ĐœĐžĐ”ĐŒ Đž ĐżĐŸĐČŃŃĐ”ĐœĐœŃĐŒ ĐžĐœĐŽĐ”ĐșŃĐŸĐŒ «ŃалОŃ/бДЎŃĐŸÂ», гОпДŃŃŃОглОŃĐ”ŃĐžĐŽĐ”ĐŒĐžĐ”Đč. ĐĄŃĐ”ĐŽĐœĐžĐ” Đ·ĐœĐ°ŃĐ”ĐœĐžŃ ĐžĐœĐŽĐ”ĐșŃĐ° ĐĐ”ŃлД ĐČŃŃĐ” Ń ĐœĐŸŃĐžŃДлДĐč ĐŽĐ°ĐœĐœĐŸĐłĐŸ ĐłĐ”ĐœĐŸŃОпа ĐżĐŸ ŃŃĐ°ĐČĐœĐ”ĐœĐžŃ Ń ĐœĐŸŃĐžŃДлŃĐŒĐž ĐłĐ”ĐœĐŸŃОпа ID. ĐŁ ĐłĐŸĐŒĐŸĐ·ĐžĐłĐŸŃ ĐżĐŸ ĐžĐœŃĐ”ŃŃОО ŃŃĐ”ĐŽĐœĐžĐ” ĐżĐŸĐșĐ°Đ·Đ°ŃДлО ĐŸĐșŃŃĐ¶ĐœĐŸŃŃĐž ŃалОО ĐŸĐșазалОŃŃ ĐŒĐ”ĐœŃŃĐ”, ŃĐ”ĐŒ Ń ĐłĐŸĐŒĐŸĐ·ĐžĐłĐŸŃ ĐżĐŸ ЎДлДŃОО Đž Ń ĐłĐ”ŃĐ”ŃĐŸĐ·ĐžĐłĐŸŃ. ĐĄŃĐ”ĐŽĐœĐžĐ” ŃŃĐŸĐČĐœĐž ŃŃОглОŃĐ”ŃĐžĐŽĐŸĐČ, ĐžĐœĐŽĐ”ĐșŃĐ° Đ°ŃĐ”ŃĐŸĐłĐ”ĐœĐœĐŸŃŃĐž, Ń
ĐŸĐ»Đ”ŃŃĐ”ŃĐžĐœĐ° Đ»ĐžĐżĐŸĐżŃĐŸŃĐ”ĐžĐœĐŸĐČ ĐŸŃĐ”ĐœŃ ĐœĐžĐ·ĐșĐŸĐč ĐżĐ»ĐŸŃĐœĐŸŃŃĐž бŃлО ĐČŃŃĐ” Ń Đ»ĐžŃ Ń ĐłĐ”ĐœĐŸŃĐžĐżĐŸĐŒ DD.ĐĐ°ĐșĐ»ŃŃĐ”ĐœĐžĐ”. Đ ĐżĐŸĐżŃĐ»ŃŃОО ŃĐŸŃŃĐ”ĐČ ĐŒĐ°ŃĐșĐ”ŃĐŸĐŒ ĐłĐ”ĐœĐ”ŃĐžŃĐ”ŃĐșĐŸĐč ĐżŃДЎŃĐ°ŃĐżĐŸĐ»ĐŸĐ¶Đ”ĐœĐœĐŸŃŃĐž Đș ĐŸĐ¶ĐžŃĐ”ĐœĐžŃ, ĐœĐ°ŃŃŃĐ”ĐœĐžŃ ŃĐ°ŃĐżŃĐ”ĐŽĐ”Đ»Đ”ĐœĐžŃ Đ¶ĐžŃĐŸĐČĐŸĐč ŃĐșĐ°ĐœĐž Đž гОпДŃŃŃОглОŃĐ”ŃĐžĐŽĐ”ĐŒĐžĐž ŃĐČĐ»ŃĐ”ŃŃŃ Đ°Đ»Đ»Đ”Đ»Ń D ĐłĐ”ĐœĐ° Đ°2Đ-Đ°ĐŽŃĐ”ĐœĐŸŃĐ”ŃДпŃĐŸŃĐ°
ĐĐŸĐŽĐ”Đ»Ń Đ±ĐžĐŸĐŒĐ”ĐŽĐžŃĐžĐœŃĐșĐŸĐłĐŸ ĐșлДŃĐŸŃĐœĐŸĐłĐŸ ĐżŃĐŸĐŽŃĐșŃĐ° ĐŽĐ»Ń ĐŽĐŸĐșĐ»ĐžĐœĐžŃĐ”ŃĐșĐžŃ ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐč ĐœĐ° ĐșŃŃĐżĐœĐŸĐŒ Đ»Đ°Đ±ĐŸŃĐ°ŃĐŸŃĐœĐŸĐŒ жОĐČĐŸŃĐœĐŸĐŒ
Objective: to develop a model of a biomedical cell product that is consistent with the «homologous drug» strategy based on protocols for preparing the cell component and scaffold carrier for preclinical studies on a large laboratory animal (pig). Materials and methods. Biomedical cell products and skin equivalents (SE), were formed using plasma cryoprecipitate prepared from blood plasma of healthy donors and mesenchymal stem cells (MSCs) of human adipose tissue. Cryoprecipitate from pig blood plasma and human adipose tissue-derived MSCs were used  to form model skin equivalents (mSE). Bright-field microscopy, phase-contrast microscopy (Leica DMI 3000B) and fluorescence microscopy (Cytation 5 imager; BioTek, USA) were used to monitor the state of cells in the culture and in the composition of the equivalents. Scaffolds for equivalents were tested for cytotoxicity (MTT test, direct contact method). The cell distribution density was characterized by authorâs method (Patent No. 2675376 of the Russian Federation). Results. An mSE was developed for preclinical studies on a large laboratory animal (pig). In the mSE, components that change from halogen to xenogenic conditions during transplantation to the animal were replaced. A comprehensive approach to preparing mSE was presented. It includes sampling of primary pig biomaterial, extraction and characterization of adipose tissue-derived MSCs, preparation of a scaffold carrier for the corresponding «homologous drug» strategy. Cytotoxicity of the mSE scaffold was evaluated. It was shown that mSE provides mechanical support (similar to SE) to cells, as well as comparable development of cellular events during cultivation. Conclusion. A model of a biomedical cell product was developed. This model is consistent with the «homologous drug» strategy for preclinical studies on a large laboratory animal (pig). The paper presented a comprehensive approach to developing a model equivalent based on protocols for preparation and testing of the cellular component, the scaffold carrier and the ready-to-use model equivalent.ЊДлŃ: ŃĐ°Đ·ŃĐ°Đ±ĐŸŃĐ°ŃŃ ĐŒĐŸĐŽĐ”Đ»Ń Đ±ĐžĐŸĐŒĐ”ĐŽĐžŃĐžĐœŃĐșĐŸĐłĐŸ ĐșлДŃĐŸŃĐœĐŸĐłĐŸ ĐżŃĐŸĐŽŃĐșŃĐ°, ŃĐŸĐłĐ»Đ°ŃŃŃŃŃŃŃŃ ŃĐŸ ŃŃŃĐ°ŃДгОДĐč Â«ĐłĐŸĐŒĐŸĐ»ĐŸĐłĐžŃĐœŃĐč ĐżŃДпаŃĐ°Ń» ĐœĐ° ĐŸŃĐœĐŸĐČĐ” ĐżŃĐŸŃĐŸĐșĐŸĐ»ĐŸĐČ ĐżĐŸĐŽĐłĐŸŃĐŸĐČĐșĐž ĐșлДŃĐŸŃĐœĐŸĐč ŃĐŸŃŃĐ°ĐČĐ»ŃŃŃĐ”Đč Đž ŃĐșĐ°ŃŃĐŸĐ»ĐŽĐ°-ĐœĐŸŃĐžŃĐ”Đ»Ń ĐŽĐ»Ń ĐŽĐŸĐșĐ»ĐžĐœĐžŃĐ”ŃĐșĐžŃ
ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐč ĐœĐ° ĐșŃŃĐżĐœĐŸĐŒ Đ»Đ°Đ±ĐŸŃĐ°ŃĐŸŃĐœĐŸĐŒ жОĐČĐŸŃĐœĐŸĐŒ (ŃĐČĐžĐœŃĐ”). ĐĐ°ŃĐ”ŃĐžĐ°Đ»Ń Đž ĐŒĐ”ŃĐŸĐŽŃ. ĐĐžĐŸĐŒĐ”ĐŽĐžŃĐžĐœŃĐșОД ĐșлДŃĐŸŃĐœŃĐ” ĐżŃĐŸĐŽŃĐșŃŃ â ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃŃ ĐșĐŸĐ¶Đž (ĐĐ) ŃĐŸŃĐŒĐžŃĐŸĐČалО Ń ĐžŃĐżĐŸĐ»ŃĐ·ĐŸĐČĐ°ĐœĐžĐ”ĐŒ ĐșŃĐžĐŸĐżŃĐ”ŃОпОŃĐ°ŃĐ° ĐżĐ»Đ°Đ·ĐŒŃ ĐșŃĐŸĐČĐž Đ·ĐŽĐŸŃĐŸĐČŃŃ
ĐŽĐŸĐœĐŸŃĐŸĐČ Đž ĐŒĐ”Đ·Đ”ĐœŃ
ĐžĐŒĐ°Đ»ŃĐœŃŃ
ŃŃĐČĐŸĐ»ĐŸĐČŃŃ
ĐșлДŃĐŸĐș (MSCs) жОŃĐŸĐČĐŸĐč ŃĐșĐ°ĐœĐž ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ°. ĐĐ»Ń ŃĐŸŃĐŒĐžŃĐŸĐČĐ°ĐœĐžŃ ĐŒĐŸĐŽĐ”Đ»ŃĐœŃŃ
ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃĐŸĐČ ĐșĐŸĐ¶Đž (ĐŒĐĐ) ĐžŃĐżĐŸĐ»ŃĐ·ĐŸĐČалО ĐșŃĐžĐŸĐżŃĐ”ŃОпОŃĐ°Ń ĐżĐ»Đ°Đ·ĐŒŃ ĐșŃĐŸĐČĐž ŃĐČĐžĐœĐ”Đč Đž MSCs жОŃĐŸĐČĐŸĐč ŃĐșĐ°ĐœĐž ŃĐČĐžĐœĐ”Đč. ĐаблŃĐŽĐ”ĐœĐžĐ” Đ·Đ° ŃĐŸŃŃĐŸŃĐœĐžĐ”ĐŒ ĐșлДŃĐŸĐș ĐČ ĐșŃĐ»ŃŃŃŃĐ” Đž ĐČ ŃĐŸŃŃĐ°ĐČĐ” ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃĐŸĐČ ĐżŃĐŸĐČĐŸĐŽĐžĐ»Đž Ń ĐžŃĐżĐŸĐ»ŃĐ·ĐŸĐČĐ°ĐœĐžĐ”ĐŒ ĐŒĐ”ŃĐŸĐŽĐŸĐČ ŃĐČĐ”ŃĐ»ĐŸĐłĐŸ ĐżĐŸĐ»Ń, ŃĐ°Đ·ĐŸĐČĐŸĐłĐŸ ĐșĐŸĐœŃŃĐ°ŃŃĐ° (Leica DMI 3000B) Đž ŃĐ»ŃĐŸŃĐ”ŃŃĐ”ĐœŃĐœĐŸĐč ĐŒĐžĐșŃĐŸŃĐșĐŸĐżĐžĐž (ĐžĐŒĐžĐŽĐ¶Đ”Ń Cytation 5; BioTek, USA). ĐĄĐșĐ°ŃŃĐŸĐ»ĐŽŃ ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃĐŸĐČ ŃĐ”ŃŃĐžŃĐŸĐČалО ĐœĐ° ŃĐžŃĐŸŃĐŸĐșŃĐžŃĐœĐŸŃŃŃ (Đйй-ŃĐ”ŃŃ, ĐŒĐ”ŃĐŸĐŽ ĐżŃŃĐŒĐŸĐłĐŸ ĐșĐŸĐœŃĐ°ĐșŃĐ°). Đ„Đ°ŃĐ°ĐșŃĐ”ŃĐžŃŃĐžĐșŃ ĐżĐ»ĐŸŃĐœĐŸŃŃĐž ŃĐ°ŃĐżŃĐ”ĐŽĐ”Đ»Đ”ĐœĐžŃ ĐșлДŃĐŸĐș ĐżŃĐŸĐČĐŸĐŽĐžĐ»Đž Đ°ĐČŃĐŸŃŃĐșĐžĐŒ ŃĐżĐŸŃĐŸĐ±ĐŸĐŒ (ĐĐ°Ń. â 2675376 РЀ). РДзŃĐ»ŃŃĐ°ŃŃ. Đ Đ°Đ·ŃĐ°Đ±ĐŸŃĐ°Đœ ĐŒĐŸĐŽĐ”Đ»ŃĐœŃĐč ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃ ĐșĐŸĐ¶Đž (ĐŒĐĐ) ĐŽĐ»Ń ĐżŃĐŸĐČĐ”ĐŽĐ”ĐœĐžŃ ĐŽĐŸĐșĐ»ĐžĐœĐžŃĐ”ŃĐșĐžŃ
ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐč ĐœĐ° ĐșŃŃĐżĐœĐŸĐŒ Đ»Đ°Đ±ĐŸŃĐ°ŃĐŸŃĐœĐŸĐŒ жОĐČĐŸŃĐœĐŸĐŒ (ŃĐČĐžĐœŃĐ”). Đ ĐŒĐĐ Đ·Đ°ĐŒĐ”ŃĐ”ĐœŃ ĐșĐŸĐŒĐżĐŸĐœĐ”ĐœŃŃ, пДŃĐ”Ń
ĐŸĐŽŃŃОД Оз Đ°Đ»ĐŸĐłĐ”ĐœĐœŃŃ
ŃŃĐ»ĐŸĐČĐžĐč ĐČ ĐșŃĐ”ĐœĐŸĐłĐ”ĐœĐœŃĐ” ĐżŃĐž ŃŃĐ°ĐœŃĐżĐ»Đ°ĐœŃĐ°ŃОО жОĐČĐŸŃĐœĐŸĐŒŃ. ĐŃДЎŃŃĐ°ĐČĐ»Đ”Đœ ĐșĐŸĐŒĐżĐ»Đ”ĐșŃĐœŃĐč ĐżĐŸĐŽŃ
ĐŸĐŽ ĐŽĐ»Ń ĐżĐŸĐŽĐłĐŸŃĐŸĐČĐșĐž ĐŒĐĐ, ĐČĐșĐ»ŃŃĐ°ŃŃĐžĐč Đ·Đ°Đ±ĐŸŃ ĐżĐ”ŃĐČĐžŃĐœĐŸĐłĐŸ Đ±ĐžĐŸĐŒĐ°ŃĐ”ŃОала ŃĐČĐžĐœŃĐž, ĐČŃĐŽĐ”Đ»Đ”ĐœĐžĐ” Đž Ń
Đ°ŃĐ°ĐșŃĐ”ŃĐžŃŃĐžĐșŃ MSCs жОŃĐŸĐČĐŸĐč ŃĐșĐ°ĐœĐž, ĐżĐŸĐŽĐłĐŸŃĐŸĐČĐșŃ ŃĐșĐ°ŃŃĐŸĐ»ĐŽĐ°-ĐœĐŸŃĐžŃДлŃ, ŃĐŸĐŸŃĐČĐ”ŃŃŃĐČŃŃŃĐ”ĐłĐŸ ŃŃŃĐ°ŃДгОО Â«ĐłĐŸĐŒĐŸĐ»ĐŸĐłĐžŃĐœŃĐč ĐżŃДпаŃĐ°Ń». ĐŃĐŸĐČĐ”ĐŽĐ”ĐœĐ° ĐŸŃĐ”ĐœĐșĐ° ŃĐžŃĐŸŃĐŸĐșŃĐžŃĐœĐŸŃŃĐž ŃĐșĐ°ŃŃĐŸĐ»ĐŽĐ° ĐŒĐĐ. ĐĐŸĐșĐ°Đ·Đ°ĐœĐŸ, ŃŃĐŸ ĐŒĐĐ ĐŸĐ±Đ”ŃпДŃĐžĐČĐ°Đ”Ń Đ°ĐœĐ°Đ»ĐŸĐłĐžŃĐœŃŃ ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃŃ ĐșĐŸĐ¶Đž (ĐĐ) ĐŒĐ”Ń
Đ°ĐœĐžŃĐ”ŃĐșŃŃ ĐżĐŸĐŽĐŽĐ”ŃжĐșŃ ĐșлДŃĐŸĐș Đž ŃĐŸĐżĐŸŃŃĐ°ĐČĐžĐŒĐŸĐ” ŃĐ°Đ·ĐČĐžŃОД ĐșлДŃĐŸŃĐœŃŃ
ŃĐŸĐ±ŃŃĐžĐč ĐżŃĐž ĐșŃĐ»ŃŃĐžĐČĐžŃĐŸĐČĐ°ĐœĐžĐž. ĐŃĐČĐŸĐŽ. Đ Đ°Đ·ŃĐ°Đ±ĐŸŃĐ°ĐœĐ° ĐŒĐŸĐŽĐ”Đ»Ń Đ±ĐžĐŸĐŒĐ”ĐŽĐžŃĐžĐœŃĐșĐŸĐłĐŸ ĐșлДŃĐŸŃĐœĐŸĐłĐŸ ĐżŃĐŸĐŽŃĐșŃĐ°, ŃĐŸĐłĐ»Đ°ŃŃŃŃĐ°ŃŃŃ ŃĐŸ ŃŃŃĐ°ŃДгОДĐč Â«ĐłĐŸĐŒĐŸĐ»ĐŸĐłĐžŃĐœŃĐč ĐżŃДпаŃĐ°Ń» ĐŽĐ»Ń ĐŽĐŸĐșĐ»ĐžĐœĐžŃĐ”ŃĐșĐžŃ
ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐč ĐœĐ° ĐșŃŃĐżĐœĐŸĐŒ Đ»Đ°Đ±ĐŸŃĐ°ŃĐŸŃĐœĐŸĐŒ жОĐČĐŸŃĐœĐŸĐŒ (ŃĐČĐžĐœŃĐ”). ĐŃДЎŃŃĐ°ĐČĐ»Đ”Đœ ĐșĐŸĐŒĐżĐ»Đ”ĐșŃĐœŃĐč ĐżĐŸĐŽŃ
ĐŸĐŽ, ĐŽĐ»Ń ŃĐ°Đ·ŃĐ°Đ±ĐŸŃĐșĐž ĐŒĐŸĐŽĐ”Đ»ŃĐœĐŸĐłĐŸ ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃĐ° ĐŸŃĐœĐŸĐČĐ°ĐœĐœŃĐč ĐœĐ° ĐżŃĐŸŃĐŸĐșĐŸĐ»Đ°Ń
ĐżĐŸĐŽĐłĐŸŃĐŸĐČĐșĐž Đž ŃĐ”ŃŃĐžŃĐŸĐČĐ°ĐœĐžŃ ĐșлДŃĐŸŃĐœĐŸĐč ŃĐŸŃŃĐ°ĐČĐ»ŃŃŃĐ”Đč, ŃĐșĐ°ŃŃĐŸĐ»ĐŽĐ°-ĐœĐŸŃĐžŃĐ”Đ»Ń Đž ĐłĐŸŃĐŸĐČĐŸĐłĐŸ ĐŒĐŸĐŽĐ”Đ»ŃĐœĐŸĐłĐŸ ŃĐșĐČĐžĐČĐ°Đ»Đ”ĐœŃĐ°
Different Effect of Proteasome Inhibition on Vesicular Stomatitis Virus and Poliovirus Replication
Proteasome activity is an important part of viral replication. In this study, we examined the effect of proteasome inhibitors on the replication of vesicular stomatitis virus (VSV) and poliovirus. We found that the proteasome inhibitors significantly suppressed VSV protein synthesis, virus accumulation, and protected infected cells from toxic effect of VSV replication. In contrast, poliovirus replication was delayed, but not diminished in the presence of the proteasome inhibitors MG132 and Bortezomib. We also found that inhibition of proteasomes stimulated stress-related processes, such as accumulation of chaperone hsp70, phosphorylation of eIF2α, and overall inhibition of translation. VSV replication was sensitive to this stress with significant decline in replication process. Poliovirus growth was less sensitive with only delay in replication. Inhibition of proteasome activity suppressed cellular and VSV protein synthesis, but did not reduce poliovirus protein synthesis. Protein kinase GCN2 supported the ability of proteasome inhibitors to attenuate general translation and to suppress VSV replication. We propose that different mechanisms of translational initiation by VSV and poliovirus determine their sensitivity to stress induced by the inhibition of proteasomes. To our knowledge, this is the first study that connects the effect of stress induced by proteasome inhibition with the efficiency of viral infection
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field
EXPERIENCE OF ORGANIZING OF THE RADIATION SITUATION MONITORING, DEVELOPMENT AND IMPLEMENTATION OF MEASURES TO MINIMIZE RISKS OF RADIATION EXPOSURE OF THE MAGADAN REGION POPULATION RELATED TO THE FUKUSHIMA ACCIDENT BY THE ADMINISTRATION OF THE FEDERAL SERVICE FOR SURVEILLANCE ON CONSUMER RIGHTS PROTECTION AND HUMAN WELL-BEING IN MAGADAN REGION AND FEDERAL HEALTH ORGANIZATION "CENTER OF HYGIENE AND EPIDEMIOLOGY IN MAGADAN REGION"
The article presents results of activities of the Administration of the Federal Service for Surveillance on Consumer Rights Protection and Human Well-being in Magadan region and the Federal Health Organization "Center of Hygiene and Epidemiology in Magadan region" in the context of monitoring of the radiation situation in the Magadan region from 12.03.2011 in connection with the Fukushima accident in Japan. The authors present the data on radiological laboratory studies, the analysis of performed organizational activities, the results of co-operation with the state and other regulatory authorities
Biomedical cell product model for preclinical studies carried out on a large laboratory animal
Objective: to develop a model of a biomedical cell product that is consistent with the «homologous drug» strategy based on protocols for preparing the cell component and scaffold carrier for preclinical studies on a large laboratory animal (pig). Materials and methods. Biomedical cell products and skin equivalents (SE), were formed using plasma cryoprecipitate prepared from blood plasma of healthy donors and mesenchymal stem cells (MSCs) of human adipose tissue. Cryoprecipitate from pig blood plasma and human adipose tissue-derived MSCs were used  to form model skin equivalents (mSE). Bright-field microscopy, phase-contrast microscopy (Leica DMI 3000B) and fluorescence microscopy (Cytation 5 imager; BioTek, USA) were used to monitor the state of cells in the culture and in the composition of the equivalents. Scaffolds for equivalents were tested for cytotoxicity (MTT test, direct contact method). The cell distribution density was characterized by authorâs method (Patent No. 2675376 of the Russian Federation). Results. An mSE was developed for preclinical studies on a large laboratory animal (pig). In the mSE, components that change from halogen to xenogenic conditions during transplantation to the animal were replaced. A comprehensive approach to preparing mSE was presented. It includes sampling of primary pig biomaterial, extraction and characterization of adipose tissue-derived MSCs, preparation of a scaffold carrier for the corresponding «homologous drug» strategy. Cytotoxicity of the mSE scaffold was evaluated. It was shown that mSE provides mechanical support (similar to SE) to cells, as well as comparable development of cellular events during cultivation. Conclusion. A model of a biomedical cell product was developed. This model is consistent with the «homologous drug» strategy for preclinical studies on a large laboratory animal (pig). The paper presented a comprehensive approach to developing a model equivalent based on protocols for preparation and testing of the cellular component, the scaffold carrier and the ready-to-use model equivalent